What is Medrhythms?
Medrhythms operates at the intersection of neuroscience and digital health, developing next-generation therapeutics designed to improve brain health and functional mobility. The company's core technology platform utilizes a sophisticated blend of music, sensors, and software to deliver Rhythmic Auditory Stimulation (RAS), a proven clinical approach for patients suffering from stroke, Parkinson's disease, and other neurologic injuries. By transforming patient care through personalized, culturally rich music libraries, Medrhythms provides a non-invasive, highly accessible solution for individuals seeking to reclaim independence and improve their quality of life. The firm's market position is bolstered by its commitment to clinical rigor and its ability to bridge the gap between traditional rehabilitation and modern digital health solutions.
How much funding has Medrhythms raised?
Medrhythms has raised a total of $36.6M across 4 funding rounds:
Series A
$5.3M
Series B
$27M
Stock/Share Issuance
$3.3M
Debt
$1M
Series A (2018): $5.3M with participation from Jean Hoffman and Peter J. Werth
Series B (2021): $27M led by Bose Ventures, Advantage Capital, Morningside Venture Capital, Global Brain, and Werth Family Investment Associates
Stock/Share Issuance (2026): $3.3M, investors not publicly disclosed
Debt (2026): $1M, investors not publicly disclosed
Key Investors in Medrhythms
Global Brain
Global Brain is an independent venture capital firm that specializes in supporting startups to achieve global success through hands-on assistance and collaboration with large corporations.
Morningside Venture Capital
Morningside Venture Capital is a private equity and venture capital firm established in 1986, specializing in early-stage technology company investments.
Advantage Capital
Advantage Capital Partners is a venture capital firm that invests in cleantech, communication, energy, information technology, and life sciences industries.
What's next for Medrhythms?
With the infusion of this recent capital, Medrhythms is well-positioned to accelerate its clinical development pipeline and expand its reach within the global healthcare market. The strategic focus will likely shift toward scaling its digital therapeutic platform to accommodate a broader range of neurologic conditions while deepening its integration with existing healthcare provider networks. As the company moves beyond its initial growth phases, the emphasis will remain on securing regulatory milestones and demonstrating long-term efficacy in patient outcomes. This financial backing provides the necessary runway to refine its software algorithms and enhance the personalization features of its RAS technology, ensuring that Medrhythms remains at the forefront of the rapidly evolving digital medicine landscape.
See full Medrhythms company page
